Small-cap healthcare and digital Assets play Xenitra Limited (ASX:XEN) has firmed up financing to support its next stage of growth, announcing it has received commitments from institutional, professional and sophisticate

d investors to raise $1.25 million through a Placement. The Capital injection is earmarked to accelerate the company’s over-the-counter (OTC) medicines expansion, scale its OPAL real-world-asset (RWA) token ecosystem across new brands, and to provide Working Capital for ongoing operations.

While the placement is modest in size by ASX standards, it provides Xenitra with the runway to execute on a dual-track strategy that combines consumer healthcare commercialisation with an emerging digital asset platform. For investors monitoring micro-cap stories at the intersection of healthcare, consumer goods and Web3 infrastructure, the announcement marks a tangible funding milestone.

Following the update, XEN share price dropped 25% to AUD 0.003 per share during the Trading session on 7 May 2026.

Placement details: pricing, structure and shares on issue

Under the terms of the placement, Xenitra will issue up to 416,666,667 fully paid ordinary shares at an issue price of $0.003 per share, raising $1.25 million before costs. The placement also includes one attaching unquoted option for every two placement shares, with the Options exercisable at $0.004 each and expiring on 2 April 2028. The options will be issued subject to Shareholder approval.

The placement shares will be issued utilising the company’s existing capacity under ASX Listing Rule 7.1, allowing the raise to be completed without the need for an immediate shareholder vote on the Equity component. The issue of the attaching options, however, will require shareholder approval through the usual notice of meeting process.

Lead manager and fee structure

Novus Capital Limited acted as sole lead manager to the placement and is entitled to a management and selling fee of 6% of the placement amount. In addition, 30,000,000 options and 15,000,000 shares will be issued to Novus, or its nominees, subject to shareholder approval. This combination of cash fee and equity is consistent with prevailing market practice for small-cap raises and aligns the lead manager’s incentives with the company’s post-raise share price performance.

Use of proceeds: OTC medicines, OPAL token rollout and working capital

Xenitra has set out four priorities for the deployment of the new capital. First, the company plans to accelerate the expansion of its OTC medicines portfolio. Second, it intends to scale the OPAL real-world-asset token ecosystem across new brands. Third, the funds will support working capital and infrastructure for growth, and fourth, they will cover the costs of the placement itself.

Each of these workstreams plays a different role in the broader Xenitra strategy, but together they reflect the company’s ambition to combine traditional consumer healthcare distribution with newer digital asset infrastructure designed to tokenise real-world assets and Brand-related rights.

OTC medicines expansion

Over-the-counter medicines represent a regulated but high-throughput segment of consumer healthcare, particularly in jurisdictions where consumers can access common analgesics, cold and flu treatments, vitamins and other supplements directly from pharmacy and grocery channels. Successfully expanding an OTC range typically requires a combination of regulatory clearances, Supply chain reliability, brand Investment and channel partnerships.

Xenitra has not, in this announcement, disclosed specific new product launches or therapeutic categories targeted by the OTC expansion. However, the deployment of placement proceeds toward acceleration of this expansion suggests that the company sees the consumer healthcare opportunity as scalable and worth allocating fresh capital to in the near term.

OPAL real-world-asset token ecosystem

The second pillar of the use-of-proceeds is the scaling of Xenitra’s OPAL RWA token ecosystem across new brands. Real-world-asset tokenisation has emerged as a fast-growing theme in the digital asset sector, with the underlying technology used to represent ownership, Revenue rights or access to physical or commercial assets through tokens issued on a blockchain.

By rolling the OPAL ecosystem out across additional brands, Xenitra appears to be positioning the platform as a multi-tenant infrastructure layer rather than a single-asset solution. The detail of the platform’s architecture, governance and token Economics has not been the subject of this particular ASX release, and investors should refer to Xenitra’s earlier announcements and disclosures for context. As with any emerging digital asset initiative, regulatory, technical and adoption risks remain a feature of the investment proposition.

Working capital and infrastructure for growth

Working capital and infrastructure spend will support the day-to-day operations needed to deliver on both the OTC and OPAL workstreams, including expanded staffing, technology infrastructure, Marketing and corporate overheads. Maintaining adequate working capital is particularly important for an emerging company juggling product launches, regulatory compliance and digital platform development.

Strategic context: combining consumer healthcare and digital asset infrastructure

Xenitra’s strategy stands out among ASX-listed micro-caps for its hybrid focus on regulated consumer healthcare and tokenised real-world assets. The combination is unusual: most listed peers either pursue specialty pharma or digital assets exclusively, and integration of the two requires careful management of regulatory, brand and technology considerations.

If executed effectively, the integrated model could enable Xenitra to use its OTC product portfolio as a foundation for tokenised brand or revenue-linked instruments via the OPAL ecosystem, potentially opening new commercial relationships with brand owners, distributors and digital asset participants. Conversely, missteps in either domain could weigh on the broader narrative, given the relatively small Balance Sheet and capital base of the company.

Why the announcement matters to investors

For investors monitoring Xenitra (ASX:XEN), the placement is significant on several fronts. It signals continued institutional, professional and sophisticated investor interest in the story, despite challenging conditions for many micro-cap raises. It also provides cash to fund near-term operational priorities, reducing the immediate risk of work needing to be paused or scaled back.

At the same time, the issue of up to 416,666,667 new shares at $0.003 represents meaningful new equity supply for a small company. Existing shareholders will need to weigh the benefits of accelerated growth against the dilution implied by the placement and any subsequent issue of options if shareholder approval is granted. As with any small-cap capital raise, prospective investors should consider their own circumstances and seek appropriate financial advice; nothing in this article constitutes investment advice or a recommendation.

Sector context: micro-cap raises in 2026

Capital Markets conditions for ASX micro-caps have been mixed through the early part of 2026, with selective Demand for differentiated growth stories and relatively cautious appetite for unproven Business models. Sub-$2 million raises at deeply discounted issue prices are not unusual at this end of the market and typically reflect a focus on funding immediate operational priorities rather than transformational expansions.

Within the consumer healthcare space, OTC products remain a steady source of revenue across pharmacies, grocery channels and E-commerce platforms. Margins and competition vary by category, but successful brand-building can lead to durable cash flows. In the digital assets segment, real-world-asset tokenisation has attracted growing institutional and regulatory attention, with policy frameworks evolving in Australia and abroad to address custody, disclosure and consumer protection issues.

Confirmed facts versus expectations

The confirmed facts in this announcement are clear: Xenitra has received commitments to raise $1.25 million via a placement; the placement involves up to 416,666,667 shares at $0.003, with one attaching unquoted option for every two shares at an exercise price of $0.004 and expiring on 2 April 2028; the options are subject to shareholder approval; Novus Capital is the sole lead manager and will receive a 6% fee plus 30 million options and 15 million shares (subject to shareholder approval); and the proceeds will be used for the OTC expansion, OPAL ecosystem scaling, working capital and placement costs.

What remains forward-looking includes any specific outcomes from the OTC expansion, the rollout schedule and uptake of the OPAL token ecosystem across new brands, and the eventual exercise (or otherwise) of the attaching options at $0.004 by their April 2028 expiry. Investors should treat these as company plans and expectations rather than guaranteed outcomes.

Indicative timing and shareholder considerations

While the announcement does not provide a detailed timetable for completion of the placement, the placement shares will be issued under existing Listing Rule 7.1 capacity, suggesting that allotment can occur relatively promptly subject to settlement formalities. The issuance of attaching options to placees, and of shares and options to Novus or its nominees, will require shareholder approval at a future meeting and will be the subject of separate disclosures, including the notice of meeting and any associated independent expert reports if required.

Existing shareholders should review subsequent disclosures from the company carefully, particularly around dilution, the structure of the OPAL token rollout, regulatory approvals associated with the OTC product expansion and any updates on operational metrics.

Risk and execution considerations

Capital raises of this scale do not, on their own, guarantee successful commercial outcomes. Execution on both the OTC and OPAL workstreams will require disciplined cost management, deep regulatory engagement and continued ability to attract and retain talent capable of bridging consumer healthcare and digital asset domains. Smaller raises can also necessitate further capital events down the track, depending on operational cadence.

From a macro perspective, micro-cap performance in 2026 has remained sensitive to Interest Rate expectations, Liquidity conditions and the relative attractiveness of larger-capitalised peers. Companies pursuing dual-track strategies that combine multiple emerging themes can offer optionality, but they also tend to require investors to underwrite multiple sets of execution risks at the same time. Xenitra’s ability to communicate operational milestones clearly and reliably will be an important Factor in maintaining engagement with both retail and institutional shareholders as the next phase of growth unfolds.

What to watch next

Looking ahead, key markers for shareholders and prospective investors to monitor include: settlement and allotment of the placement shares; the timing and outcome of any shareholder meeting required to approve the issue of attaching options and lead manager equity; specific updates on OTC product launches, distribution partnerships or regulatory approvals; and the rollout of the OPAL real-world-asset token ecosystem across additional brands, including any disclosures regarding token economics, security infrastructure and partner onboarding.

Investors will also be watching for any operational metrics that the company chooses to disclose, such as revenue contributions from new OTC products, transaction or user metrics for the OPAL platform, and updates to working capital and cash burn. Each of these data points will help the market form a more granular view of how the placement proceeds are being deployed and the pace at which the company is moving toward sustainable, scaled commercialisation.

Outlook and conclusion

The $1.25 million placement is a relatively small but strategically important step for Xenitra Limited (ASX:XEN). It crystallises continued investor support, provides funding for the next phase of OTC growth and OPAL ecosystem expansion, and sets up a series of operational milestones that will become important benchmarks for assessing the company’s execution over the coming year.

For investors and observers of the broader ASX micro-cap landscape, the announcement is also a useful reminder of how hybrid business models combining traditional regulated industries with emerging digital asset infrastructure are increasingly common at the speculative end of the market. As Xenitra deploys the new capital, future updates around new product launches, brand partnerships through OPAL and any associated digital asset offerings will be important markers of progress.